The combination of BPC-157 and TB-500 — commonly called the Wolverine Stack — is one of the most widely used peptide protocols for injury recovery. The two peptides target different bottlenecks in the healing process: BPC-157 restores blood flow to damaged tissue while TB-500 mobilizes the repair cells that rebuild it.
When tissue is damaged, the body's emergency response chokes microcirculation and traps repair cells (fibroblasts) in place. Unless new capillaries grow and those repair cells start moving again, healing stalls. BPC-157 reopens the vascular network; TB-500 directs the cells traveling on it.
Neither peptide alone covers both problems. BPC-157 restores blood supply — but without cell migration, the nutrients arrive and sit unused. TB-500 mobilizes repair cells — but without perfusion, those cells starve before they can rebuild anything. The Wolverine Stack exists because the two bottlenecks are coupled: solving one without the other produces the "half-healed" state most people know too well.
The evidence base is preclinical. BPC-157 has 36 studies in a 2025 systematic review — 35 preclinical, 1 clinical trial with 12 patients.¹ TB-4 (thymosin beta-4, the parent molecule) has roughly 50 preclinical studies and Phase 1 human safety data.² No human RCTs exist for the combination. Every stacking protocol described here is practitioner-derived, built on mechanistic rationale and clinical observation rather than controlled trials.
The named Wolverine Stack is still BPC-157 + TB-500. NAD+ belongs beside it when the injury is bigger, chronic, post-surgical, or energy-draining — because repair cells cannot build collagen, remodel tissue, or run cleanup work without enough cellular fuel.
At a Glance
| Compound | Primary Role | Dose | Frequency | Route |
|---|---|---|---|---|
| BPC-157 | Blood flow and local repair tone | 250–500 mcg | Daily | SubQ |
| TB-500 | Cell migration and tissue remodeling | 2–4 mg | 2× weekly | SubQ |
Cycle length: 6–10 weeks (TB-500), 8–12 weeks (BPC-157)
Common support layer: NAD+ 50–250 mg IM about 3×/week when recovery feels energy-limited, the injury is chronic, or the protocol is being used after a larger tissue insult. SubQ is acceptable if needed, but split into smaller doses to reduce welting and irritation.
Who This Is For
People with tendon, ligament, or soft tissue injuries who want:
- A simpler protocol focused on the two most critical repair bottlenecks
- Clear structure without managing five compounds
- A foundation that can be expanded if needed
This stack addresses vascular access and cellular mobility — the layers most injuries need first. For more complex or chronic injuries, the injury recovery protocol adds energy, collagen quality, and inflammation control.
Why These Two Together
The problem: stalled healing
After injury, the body's first reaction is containment: vessels constrict, platelets form clots, and inflammatory cells flood the site. That emergency response stops bleeding but also chokes micro-circulation, leaving the region starved of oxygen and nutrients. Unless new capillaries grow and repair cells start moving again, healing stalls in the inflammatory phase.
This is the "half-healed" state:
- Pain that waxes and wanes
- Stiffness that never fully resolves
- Tissue that feels both tight and weak
- Morning mobility that takes 20+ minutes to return
Two things need to happen for healing to restart: the tissue needs blood supply (perfusion), and repair cells need to reach the injury and organize properly (migration). BPC-157 handles the first. TB-500 handles the second.
Why not just BPC-157 alone?
BPC-157 runs as a standalone — it has the stronger individual evidence base¹ and many people report meaningful improvement from it. But BPC-157's primary effect is vascular: it signals blood vessel cells to sprout new capillaries and restores blood flow to starved tissue (angiogenic signaling¹ ³). Blood supply is necessary for healing, but not sufficient.
What BPC-157 doesn't do well is direct cell organization. Repair cells, blood vessel cells, and skin cells all need to physically move into the injury site and arrange themselves into functional tissue rather than scar. That's the TB-500 side of the bet: support the cell-movement machinery that repair depends on (actin-binding repair signal⁴).
Running BPC-157 alone is like reopening roads to a construction site but not sending workers. The materials arrive, but nothing gets built efficiently.
How BPC-157 works
BPC-157 is a 15-amino-acid fragment of a gastric protein (Body Protection Compound). It restores blood flow and creates the conditions for tissue repair through four connected effects:
It builds new blood vessels. BPC-157 signals blood vessel cells to sprout new capillaries into damaged tissue, reopening circulation that the injury response shut down (angiogenic signaling¹ ³). This is why injured areas often "warm up" within the first week — circulation is returning.
It restores blood flow through existing vessels. Beyond building new ones, BPC-157 restores nitric oxide production — the molecule that dilates blood vessels and keeps blood flowing (eNOS activation¹). More blood flow means more oxygen, more nutrients, more immune cells reaching the injury.
It helps repair cells move and anchor. Repair cells need to grab onto surrounding tissue and pull themselves toward the injury. BPC-157 activates the pathway that lets them do this (FAK-paxillin signaling⁵) — it's the difference between cells that sit in place and cells that actively migrate into damaged zones.
It calms inflammation without impairing repair. BPC-157 lowers inflammatory molecules (TNF-α and IL-6¹) without the trade-offs of NSAIDs, which impair collagen quality, or corticosteroids, which suppress the repair cells themselves. It also promotes nerve sprouting alongside new blood vessels¹ — which is why sensory "dead zones" around injuries often recover faster.
What you notice: Warmth returns to the injury site. Swelling becomes productive rather than stagnant. Scar forms in organized lines rather than chaotic bands. Sensation returns to areas that felt numb.
How TB-500 works
TB-500 is usually discussed as thymosin beta-4 fragment 17-23: the short sequence associated with repair-cell movement. That is related to full-length TB-4, but not interchangeable with it. Full-length TB-4 carries additional regions that the fragment does not, and many stronger scar-remodeling claims come from TB-4 research rather than TB-500 itself. See the TB-500 guide for details.
Where BPC-157 restores blood supply, TB-500 handles what happens next — helping the right cells reach the right place so tissue can organize.
It supports cell movement. Every cell has an internal scaffolding made of actin protein. TB-500 is used because this short region appears to support the actin-side movement signal repair cells need when they migrate into damaged tissue (actin-binding repair signal⁴).
It may help the remodeling phase. Healing is not just building new tissue. Damaged matrix has to be cleared and reorganized so new tissue can form in the right pattern. The strongest evidence for this broader cleanup/remodeling signal is with full-length TB-4, not isolated TB-500 (matrix-remodeling signal⁶).
If you have TB-4: it also shifts the immune response from destruction to construction. After injury, the first wave of immune cells (M1 macrophages) clears debris and fights infection. The second wave (M2 macrophages) rebuilds tissue and resolves inflammation. TB-4 accelerates this transition — shifting immune cells from inflammatory mode to repair mode (macrophage polarization⁴). This effect has been studied with full-length TB-4, not the isolated fragment.
If you have TB-4: it also reduces excessive scarring. TB-4 is enzymatically processed to release Ac-SDKP (fragment 1–4), which suppresses TGF-beta/Smad signaling and blocks the cells responsible for excessive scar formation (anti-fibrotic signaling⁷). TB-500 does not contain this fragment and does not produce this anti-fibrotic effect.
What you notice: Tissue softens. Fascia planes that felt glued together start gliding again. Load tolerance improves without the same next-day punishment. If scar remodeling is the main goal, product identity matters: TB-500 and full-length TB-4 should not be treated as identical.
The synergy
Each peptide addresses a bottleneck the other can't:
| Without BPC-157 | With BPC-157 | |
|---|---|---|
| Without TB-500 | No blood supply, no cell migration — healing stalls | Blood supply returns, but cells don't organize — scar tissue, adhesions |
| With TB-500 | Cells mobilize but starve — insufficient nutrients, oxygen | Both bottlenecks addressed — blood flow + cell migration = organized tissue reconstruction |
There's also a secondary interaction: BPC-157 restores vessel tone while TB-500 supports repair-cell movement.¹ ⁴ Together, they help the injury move out of the stuck inflammatory phase without relying on NSAIDs, which can weaken collagen quality, or corticosteroids, which suppress the repair cells themselves.
In a rat model, combined BPC-157 + TB-4 restored contractile function earlier than either compound alone.⁸
Dosing
| Compound | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| BPC-157 | 250–500 mcg | Daily | SubQ near injury site if safe | Higher range belongs to escalation |
| TB-500 | 2–4 mg | 2× weekly | SubQ | ≥72 hours between doses |
Cycle length: 6–10 weeks (TB-500), 8–12 weeks (BPC-157)
NAD+ companion layer: 50–250 mg IM about 3×/week when the injury is chronic, post-procedure, high-load, or recovery feels systemically draining. Inject NAD+ alone. SubQ can work, but smaller divided doses are usually better tolerated.
The peptide dosing calculator works out the exact injection volumes from vial concentration.
Why BPC-157 is daily but TB-500 is not
The two peptides work in fundamentally different ways, which is why their dosing schedules differ.
BPC-157 delivers instructions. A small dose flips a switch — it triggers repair cascades (new blood vessel formation, nitric oxide production, cell migration signaling¹) that continue running for days after the peptide itself clears. Daily dosing keeps the signaling environment active. Think of it as sending a daily message that says "keep building."
TB-500 is pulsed because the goal is a migration signal, not constant background pressure. The peptide-user convention is a milligram-scale bolus 2× per week, spaced far enough apart to avoid turning the protocol into daily noise. This is practitioner-derived dosing that fits the cell-movement model; it is not a formal human pharmacokinetic schedule.
This is why the usual practical range is 2–4 mg 2× per week, with at least 72 hours between doses.
Injection routing
Inject near the injury site when it is easy and safe to reach. BPC-157 and TB-500 are pH compatible and can be drawn into the same syringe. For injuries in difficult-to-reach locations (spine, deep hip), abdominal or thigh injection is the practical alternative.
Both peptides enter systemic circulation rapidly — they don't "stay local." Local injection may provide a higher first-pass concentration before systemic dilution, but safe placement matters more than forcing a perfect site. If the site is awkward, inflamed, bruised, or hard to access, rotate ordinary SubQ sites.
Pre-mixed blends vs separate compounds
Some vendors sell pre-mixed "wolverine blend" vials combining both peptides. These are convenient but come with trade-offs: the BPC-157-to-TB-500 ratio is fixed, the concentration of each compound can't be verified separately, and the vendor's chosen ratio is the only option. Separate vials leave more control in the protocol — particularly useful for tapering TB-500 while continuing BPC-157.
Weight-based guidance
- BPC-157: ~3–7 mcg/kg daily
- TB-500: ~0.03–0.06 mg/kg per dose
Weekly Schedule (Example)
| Compound | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| BPC-157 | 500 mcg | 500 mcg | 500 mcg | 500 mcg | 500 mcg | 500 mcg | 500 mcg |
| TB-500 | 2–4 mg | — | — | 2–4 mg | — | — | — |
The specific days are flexible; consistency matters more, with at least 72 hours between TB-500 doses. When NAD+ runs as the support layer, the convention places it on separate days or separate injections at 50–250 mg IM about 3×/week, kept out of the BPC-157/TB-500 syringe.
Timeline: What to Expect
Days 3–7
- What's happening — BPC-157 signals new capillary formation (angiogenesis¹). Blood flow begins returning to the injury site.
- What you notice — Less sharp pain; gentle warmth as circulation reopens.
- Side effects — Mild local reactions at injection site; TB-500 may cause brief lethargy (12–24 hours).²
Weeks 1–2
- What's happening — TB-500 loading phase builds up actin reserves inside cells (actin sequestration⁴). Repair cells begin migrating into the injury site. Early collagen matrix forming.
- What you notice — Less "locked" feeling. Morning stiffness fades faster — 10–15 minutes instead of 20+.
- Challenge — The internal structural changes run ahead of the visible signs; repair is happening before it shows.
Weeks 2–4
- What's happening — Early remodeling. New collagen is being laid down and organized.⁶ Immune cells have shifted from inflammatory mode to repair mode (macrophage polarization⁴), driving tissue reconstruction.
- What you notice — Tissue feels pliable, not stiff. Load tolerance rising — you can do more in PT without next-day setbacks.
- Decision point — Clear progress means staying the course; a stall routes to When Progress Stalls.
Weeks 4–8
- What's happening — Consolidation and maturation. Collagen fibers organize along lines of mechanical stress (which is why PT and progressive loading are non-negotiable during this phase).
- What you notice — Strength returning. Tissue behaves more like the original — less reactive, more resilient under load.
- Maintenance — TB-500 can taper to weekly after week 6 if stable.
How to tell if it's working
Beyond the timeline, a few specific markers track whether the stack is working:
Early signs (weeks 1–2): Warmth returning to the area. Reduced sharp pain. Morning stiffness resolving faster. The injury site feels "alive" rather than cold and stiff.
Later signs (weeks 3–4): Improved pliability on palpation. Better tolerance of gentle loading. Range of motion improvements. Less reactivity after activity — the injury stops "punishing" the next day for being used.
Plateau signals: Early improvement that levels off is a specific signal — not failure, but a sign that the vascular and migration bottlenecks are clearing while another bottleneck (energy, collagen quality, or inflammation) is now rate-limiting. See When Progress Stalls.
Supporting Factors
Peptides provide biological repair signals. The raw materials for actual tissue construction come from nutrition and mechanical loading.
| Component | Target | Why |
|---|---|---|
| Vitamin C | 500 mg AM/PM | Required cofactor for collagen cross-linking |
| Collagen peptides | 10 gdaily (30–45 min before PT) | Raw material for tissue construction⁹ |
| Glycine | 3 gdaily | Rate-limiting amino acid in collagen |
| Movement | Gentle ROM within pain-free limits | Directional stress organizes collagen fibers |
| Sleep | 7–9 hours | Angiogenesis hormones peak during deep sleep |
Movement is not optional. Collagen fibers align along lines of mechanical stress. Without controlled loading, new tissue forms as disorganized scar. Peptides and physical therapy are synergistic — neither replaces the other. Collagen peptide timing matters too: the effect is strongest 30–45 minutes before a PT session.⁹
When Progress Stalls
| Step | Where the bottleneck sits |
|---|---|
| 1 | The first checks are protein (1.6–2.2 g/kg/day), sleep (7–9 hrs), and hydration — under-eating stalls repair. |
| 2 | Injection technique and storage conditions (refrigerated, protected from light) come next. |
| 3 | Tissue warm but energy low → the NAD+ support layer |
| 4 | Collagen quality poor (mushy, not elastic) → GHK-Cu |
| 5 | Inflammation persisting (swelling after activity) → KPV |
| 6 | All three bottlenecks → the injury recovery protocol |
Extending the same protocol unchanged rarely shifts a stall. Once the Wolverine Stack has addressed perfusion and migration and something else is rate-limiting, the productive step is identifying that specific bottleneck and addressing it directly.
Managing Side Effects
| Issue | Primary Mitigation | Secondary Options |
|---|---|---|
| BPC-157 local warmth | Normal — sign of re-perfusion | Rotate sites if persistent |
| TB-500 lethargy (12–24 hrs) | Hydrate; schedule before rest day | Split into smaller doses |
| Injection site reactions | Rotate sites; check technique | Warm peptide before injection |
Side effects are generally mild. BPC-157 local warmth is actually a positive sign — it means blood flow is returning to the area.
Contraindications
The hard contraindications:
- Active cancer or malignancy within 2 years — both peptides promote new blood vessel formation (angiogenesis), which could theoretically support tumor blood supply. See cancer FAQ below.
- Pregnancy or breastfeeding — insufficient safety data
- Proliferative retinopathy — angiogenesis may worsen pathology
- Planned or very recent surgery — protocols sit until the initial clotting window has settled, unless a clinician directs otherwise
The profiles that warrant medical supervision:
- Concurrent corticosteroid use (steroids oppose tissue repair mechanisms)
- Severe cardiovascular disease
- Active autoimmune conditions — TB-500 shifts immune cell behavior (macrophage polarization⁴), which may alter immune balance unpredictably
- Therapeutic anticoagulation
Sports compliance: TB-500 is prohibited under WADA's thymosin-beta-4 / growth-factor language, and BPC-157 is WADA S0. FDA compounding status is access context, not an approval or efficacy verdict. Testing can detect metabolites of both compounds.
What Comes Next
The 6–8 week mark is the usual assessment point, and it splits three ways.
Complete (resolution): With all markers met, the protocol tapers off. Many clinicians run a 2–4 week taper rather than an abrupt stop — TB-500 frequency drops first (once weekly), then BPC-157 (every other day). Where NAD+ was added for recovery support, its frequency comes down after the injury is functionally stable rather than during the hardest remodeling weeks.
| Marker | Threshold |
|---|---|
| Pain at rest | ≤ 2/10 |
| Range of motion | ≥ 80% of contralateral |
| Post-activity edema | None within 24 hours |
| Tissue palpation | Warm and supple, no fibrotic bands |
| Morning stiffness | Resolves within 10 minutes |
Extend: Clear but incomplete progress warrants another 4 weeks on the same protocol.
Escalate: Specific bottlenecks persisting at week 4–6 despite good compliance point to adding compounds or moving to the injury recovery protocol. The transition markers — any one of them:
- Tissue warm but energy flagging (fatigue persists despite sleep/nutrition) → the NAD+ layer
- Collagen quality poor (tissue feels mushy rather than elastic under load) → GHK-Cu
- Inflammation cycling (edema returns after moderate activity despite 4+ weeks) → KPV
For chronic injuries with sleep disruption, see Tesamorelin for Injury Recovery. For neuropathic symptoms, see ARA-290 for Nerve Pain.
Storage and Handling
- Reconstitute with bacteriostatic water under clean technique (see Reconstitution Guide for step-by-step instructions)
- Refrigerate at 2–8°C after reconstitution; protect from light
- Beyond-use: 2–4 weeks refrigerated
- BPC-157 and TB-500 can be co-injected in one syringe (pH compatible)
- NAD+ should be injected alone; the solution can sting and is not a peptide-blend additive
FAQ
Where to inject the Wolverine Stack
Near the injury site when it is easy and safe, subcutaneous. BPC-157 and TB-500 are pH compatible and can go in the same syringe. For hard-to-reach injuries (spine, deep hip), abdominal or thigh injection is the practical alternative.
Both peptides enter systemic circulation rapidly — they don't "stay local." But therapeutic effect is concentration-dependent, and local injection may provide a higher first-pass concentration at the injury before dilution. See local vs systemic below for the evidence.
Can I combine BPC-157 and TB-500 in one syringe?
Yes, they're pH compatible. Many clinicians co-inject without issues. If you're unsure about stability with a specific formulation, use separate syringes. Do not mix either with acidic peptides like NAD+.
What if I'm still in a brace or boot?
Systemic injections (abdomen/thigh) are the starting point during immobilization; once movement is cleared, BPC-157 shifts closer to the injury site. Immobilization doesn't prevent peptide benefit, but collagen alignment is less organized without directional stress — the new tissue needs mechanical signals to organize properly.
Should I stop physical therapy?
No. These peptides support PT — they restore blood flow and cell migration, which makes rehab exercises more effective. The peptides provide the biological infrastructure; PT provides the directional stress signals that organize collagen into functional tissue. The two run together.
How long until I feel something?
Most people notice reduced pain and improved warmth within the first 1–2 weeks. Functional improvements (load tolerance, mobility) typically develop over weeks 3–4. Nothing felt by week 3 usually traces back to injection technique or storage conditions — peptide degradation is the most common cause of non-response — with dosing the next thing to check.
Is local injection really better than systemic?
Not proven as a clinical outcome advantage. Inject near the injury when it is easy and safe to reach. For hard-to-reach injuries, abdominal or thigh injection is the practical alternative.
The peptides don't "stay local" — they enter systemic circulation rapidly. But local injection may provide a higher first-pass concentration before dilution. Use injury-adjacent SubQ when the site is accessible and calm; use abdomen or thigh when it is not.
Can I take NSAIDs while using these peptides?
NSAIDs and these peptides work against each other. NSAIDs suppress the inflammatory phase of healing, which interferes with the signals these peptides are restoring. BPC-157 lowers inflammatory molecules directly¹ — it calms inflammation without impairing collagen quality the way NSAIDs do.
Where NSAIDs are unavoidable for acute pain, the lowest effective dose for the shortest duration limits the interference.
What about corticosteroid injections?
Corticosteroids and repair peptides work against each other. Steroids suppress repair cell activity and new blood vessel formation — exactly what BPC-157 and TB-500 promote. After a recent steroid injection, the convention is a 2–4 week gap before peptide therapy. BPC-157 can counteract corticosteroid-impaired healing in preclinical models, suggesting some compatibility where overlap is unavoidable.¹
What's the difference between TB-500 and TB-4?
TB-500 is thymosin β4 fragment 17–23 — a 7-amino-acid active fragment (~800 Da molecular weight) containing the actin-binding domain.
TB-4 is the full-length 43-amino-acid thymosin β4 protein (~4,900 Da molecular weight).
The problem: Product labels are messy. TB-500, full-length TB-4, and shorter downstream fragments are related, but they are not the same compound. Both TB-500 and TB-4 touch the repair-cell movement story, but the stronger anti-fibrotic and broader tissue-remodeling claims usually come from full-length TB-4 research.
The practical difference: the fragment contains only the actin-binding/cell-migration domain. Full-length TB-4 carries additional active sites — Ac-SDKP (anti-fibrotic, anti-inflammatory) and fragment 1–15 (anti-apoptotic) — plus ILK/Akt signaling that the fragment lacks.⁷ Both distribute systemically after subQ injection. Most clinical research uses TB-4. See the TB-500 guide for full details.
How do I know if I have real TB-500 or TB-4?
The Certificate of Analysis (COA) or a third-party lab report is the provenance check:
| What to Look For | TB-500 (Fragment) | TB-4 (Full Protein) |
|---|---|---|
| Molecular weight | ~800 Da | ~4,900 Da |
| Amino acid count | 7 amino acids | 43 amino acids |
| Sequence | LKKTETQ | Full sequence starting with SDKPDM... |
| Mass spec peak | ~800 m/z | ~4,900 m/z |
A COA showing molecular weight around 4,900 Da or 43 amino acids is TB-4 — regardless of what the label says. That is not a trivial label difference: identity changes which evidence the protocol can borrow and how confident it should be.
Do BPC-157 and TB-500 cause cancer?
No evidence of tumor promotion exists for either compound.
The concern is theoretical: both peptides promote new blood vessel formation, and tumors need blood supply to grow. A compound that builds new capillaries could theoretically feed a tumor that's already there. However, preclinical data suggests BPC-157 may actually inhibit certain tumor growth pathways.¹⁰ TB-4 research has found both growth-promoting and growth-inhibiting associations depending on tissue context.
The practical position: active cancer or a cancer history within 2 years is a precautionary contraindication for these peptides. For people without cancer history, the theoretical risk appears low — but long-term human studies that would definitively settle this question don't exist.
Should I continue after the injury feels healed?
Many clinicians run a 2–4 week taper rather than abrupt cessation. During the taper, TB-500 frequency drops first (once weekly), then BPC-157 (every other day). This lets collagen remodeling consolidate — the tissue is still maturing internally even after it feels functionally normal.
What if pain increases during the first week?
Mild increases in awareness or dull aching can occur as blood flow returns — this is the "warming up" effect as BPC-157 restores circulation to the area. A significant pain increase (>4/10), or a change in character (sharp, burning, or shooting), is the red flag that separates re-perfusion from a problem and the signal to pause and bring in a clinician.
Can I use these for chronic injuries (6+ months old)?
Yes, but expectations should be realistic. Chronic injuries often have multiple bottlenecks beyond vascular access — established scar tissue, adapted blood supply patterns, and often mitochondrial depletion. BPC-157 + TB-500 address the foundational layers. Complete chronic injury resolution often requires the injury recovery protocol with additional compounds targeting the specific bottleneck.
Are there long-term risks?
Human long-term safety data is limited. TB-4 Phase 1 trials showed safety in 84 healthy volunteers at doses well above standard protocols, but only for 10-day exposure.² No multi-month human safety studies exist for either compound.
The primary theoretical concern is promoting new blood vessel formation in contexts where it's harmful (undetected cancer, proliferative retinopathy). For healthy individuals without these conditions, no significant long-term adverse effects have been identified in clinical use. Most practitioners use defined cycles (6–12 weeks) rather than indefinite use.
Related Topics
- Injury Recovery Protocol — Expanded 3-tier framework building on the Wolverine Stack core
- Complete BPC-157 Guide — Deep dive on BPC-157 mechanism, dosing, applications
- TB-500 Guide — Standalone deep-dive on Thymosin Beta-4
- 5-Compound Protocol — Complete protocol with NAD+, GHK-Cu, KPV
- NAD+ Guide — Cellular energy for stalled healing
- GHK-Cu Guide — Copper peptide for collagen quality
- Peptide Calculator — Calculate injection volumes from vial concentration
- Where to Inject Peptides — Why injection site matters differently for BPC-157 vs TB-500
- Peptide Calculator — How to prepare peptide vials
- Peptide Stacking Guide — How the Wolverine Stack fits into the 5-axis stacking framework
References
¹ BPC-157 systematic review — 36 studies (35 preclinical, 1 clinical with 12 patients). VEGF upregulation, eNOS activation, FAK-paxillin cascade, anti-cytokine modulation. Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine." HSS J. 2025. PMC12313605
² TB-4 Phase 1 safety data — 84 healthy volunteers (54 single-dose, 30 multiple-dose) tolerated recombinant thymosin beta-4 at doses up to 25 μg/kg daily for 10 days. No serious adverse events. Half-life 0.5–2.1 hours IV. Wang D et al. "Phase I study of recombinant human thymosin β4." Ann Transl Med. 2021;9(15):1232. PMC8419156
³ BPC-157 angiogenic mechanism — VEGFR2-Akt-eNOS signaling, nitric oxide bioavailability. Reviewed in: PMC8275860
⁴ G-actin sequestration and macrophage polarization — Thymosin beta-4 binds G-actin monomers, preventing premature polymerization and maintaining reserve pools for rapid cell migration. Promotes M1→M2 macrophage shift. Goldstein AL et al. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-429. PMID 16099219
⁵ BPC-157 tendon outgrowth — FAK-paxillin signaling promotes tendon repair cell outgrowth and migration. Chang et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011. PubMed 21030672
⁶ TB-4 connective tissue organization — Thymosin beta-4 treated Achilles tendons showed uniform fiber bundles with increased collagen fibril diameters vs controls. Prevents myofibroblast appearance. Sosne G et al. "Thymosin beta4 enhances repair by organizing connective tissue." FASEB J. 2010. PubMed 20536458
⁷ TB-4 anti-fibrotic signaling — Thymosin beta-4 activates integrin-linked kinase, promotes cardiac cell migration and survival, modulates TGF-beta to reduce fibrosis. Bock-Marquette I et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair." Nature. 2004;432(7016):466-472. PMID 15282614
⁸ Combined BPC-157 + TB-4 data — Combined administration restored contractile function earlier than either compound alone. BPC-157 case series (n=17) showed symptom reduction in >90% following intra-articular injection. Rahman OF et al. "Therapeutic Peptides in Orthopaedics." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMC12753158
⁹ Collagen supplementation — Systematic review of collagen peptide effects on body composition, collagen synthesis, and recovery. Kirmani BH et al. Amino Acids. 2021. PMC8521576
¹⁰ BPC-157 and tumor risk — Narrative review of regeneration vs cancer risk. Preclinical data suggests potential anti-tumorigenic properties in some contexts. McGuire FP et al. "Regeneration or Risk?" Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC12446177
¹¹ Local concentration matters for therapeutic effect — Free systemic TB-4 at the same total dose as a fibrin-targeted nanoparticle formulation produced no functional improvement in cardiac repair — systemic dilution dropped tissue concentration below therapeutic threshold. Huang G et al. "Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles." Int J Nanomedicine. 2017;12:3023-3036. PMC5396927
This content is for educational purposes only. BPC-157 and TB-500 are not FDA-approved injury therapies. No human RCTs exist for the BPC-157 + TB-500 combination — all stacking protocols are practitioner-derived, based on mechanistic rationale and clinical observation. Consult a physician before beginning any peptide protocol, particularly if you have active cancer, autoimmune conditions, or are taking medications that affect immune function or coagulation.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.